Sclerotherapy vs laser for spider veins: choose by vessel, location, and treatment endpoint

Sclerotherapy and vascular laser treatment close small visible vessels by different routes. Sclerotherapy injects a prescription sclerosant into a leg vein; a laser sends selected light through the skin to heat a target vessel. Choose only after confirming what the visible line is, where it sits, its diameter and depth, whether larger feeder or refluxing veins matter, and which exact drug or device is proposed.¹²

A red facial line, a blue leg reticular vein, and a raised varicose tributary can all be called a “spider vein” in casual conversation. They are not the same target. The useful comparison begins with anatomy and endpoint, not with a promise that one modality is universally faster.

Define the vessel before comparing treatments

The current U.S. prescribing information for polidocanol defines spider veins as uncomplicated lower-extremity varicose veins no more than 1 millimeter in diameter and reticular veins as 1 to 3 millimeters.¹ Those label definitions are more precise than an image-search label. The product was not studied in veins larger than 3 millimeters, so a larger vessel cannot simply inherit the small-vein evidence.

If the mark has appeared suddenly, bleeds, is painful, is associated with one-sided swelling, or does not look like a typical superficial vessel, the first job is identification—not booking a cosmetic session.

Sclerotherapy treats the vessel from the inside

An injected sclerosant deliberately damages the target vein’s inner lining. The polidocanol label explains that platelets and fibrin then occlude the vein and the closed vessel is eventually replaced by connective tissue.¹ This is not a cosmetic filler injection and does not share its product, anatomy, or endpoint.

For one FDA-approved polidocanol product, the label specifies different concentrations for spider and reticular veins, a per-injection volume range, a session maximum, and post-treatment compression.¹ Those are product-specific instructions, not dosing advice for readers and not a class-wide template. The clinic should identify the exact sclerosant, concentration, formulation, route, and label that supports the plan.

Sclerotherapy can access networks that are visible beneath the surface, but access alone does not answer whether a larger feeder or refluxing pathway should be evaluated first. A careful proposal records the treated vessels, any ultrasound role, injection product, session staging, compression instructions, activity guidance, and response plan.

Laser treats through the skin

A vascular laser sends a selected wavelength through the surface. Energy absorbed by blood produces heat intended to close the vessel while cooling and pulse design help manage the surrounding skin. “Laser” is therefore incomplete without manufacturer, model, wavelength, handpiece or spot, target vessel, skin context, and treatment settings logic.

FDA’s radiation rules and a medical device’s 510(k) record answer different questions.³⁴ A device can meet radiation-product requirements without every promoted vascular use being cleared. Ask for the exact model and indications for use, then match the proposed vessel and anatomy.

Melanin also absorbs light. That does not rule out every vascular laser for darker skin; it means the wavelength, cooling, test-spot logic, recent tanning, and operator experience deserve explicit review. Treomark’s laser-and-skin-tone guide provides a broader pigment-aware framework.

The choice is often anatomical, not competitive

This is why “laser is noninvasive” does not settle the decision. Light still creates a thermal exposure in skin and vessel. Conversely, “injection is more direct” does not prove that every visible line is an appropriate vein or that every solution is approved for the proposed use.

Compare recovery as a workflow

Sclerotherapy planning may include compression, walking, activity or travel restrictions, follow-up for trapped blood, and staged sessions. The current polidocanol label includes compression and post-treatment activity instructions and lists local reactions such as bruising, irritation, discoloration, pain, itching, warmth, new small vessels, and thrombosis among reported events.¹ A provider should explain the exact product’s more serious risks and what symptoms require prompt contact.

Laser planning may include cooling, transient redness or swelling, crusting or blister response, pigment precautions, sun avoidance, and assessment of residual vessels. Those details depend on the model, wavelength, fluence and pulse structure, skin context, and treatment area; a generic vascular-laser handout is not a substitute for the exact device instructions.

In South Florida, ask how current tanning and unavoidable incidental sun exposure alter scheduling and aftercare. The answer should be practical—what to protect, for how long, and what change should prompt contact—not a promise of “zero downtime.”

Build a vessel-first consultation record

1. Name the mark. Record face or leg, color, diameter estimate, flat or raised appearance, symptoms, and how long it has been present.
2. Ask what sits upstream. Find out whether a reticular feeder, larger varicose vein, symptoms, or exam finding changes the need for venous evaluation or duplex imaging.
3. Identify the product or device. For injection, capture drug, formulation, concentration, and label. For laser, capture manufacturer, model, wavelength, and indication.
4. Define the endpoint. Specify one target vessel, a local network, a symptomatic venous problem, or cosmetic improvement; do not mix them.
5. Compare the full course. Include session staging, compression or skin care, sun and travel constraints, follow-up, and likely reasons for another modality.
6. Verify the professional and response path. Connect the operator's license and training to prescribing, injection or laser authority, supervision, records, and urgent follow-up.

Bring this one sentence to the consultation: “What exact vessel are we treating, is there a feeder or reflux question, and why does this drug or this wavelength fit its location, size, depth, and endpoint?” That answer is more useful than a modality ranking.